PL353931A1 - Mezoprogestyny (substancje modulujące receptory prMezoprogestyny (substancje modulujące receptory progesteronowe) jako składnik środków stosowanych wogesteronowe) jako składnik środków stosowanych whormonalnej terapii zastępczej (HTZ)hormonalnej terapii zastępczej (HTZ) - Google Patents

Mezoprogestyny (substancje modulujące receptory prMezoprogestyny (substancje modulujące receptory progesteronowe) jako składnik środków stosowanych wogesteronowe) jako składnik środków stosowanych whormonalnej terapii zastępczej (HTZ)hormonalnej terapii zastępczej (HTZ)

Info

Publication number
PL353931A1
PL353931A1 PL00353931A PL35393100A PL353931A1 PL 353931 A1 PL353931 A1 PL 353931A1 PL 00353931 A PL00353931 A PL 00353931A PL 35393100 A PL35393100 A PL 35393100A PL 353931 A1 PL353931 A1 PL 353931A1
Authority
PL
Poland
Prior art keywords
mesoprogestins
hrt
compositions
component
replacement therapy
Prior art date
Application number
PL00353931A
Other languages
English (en)
Other versions
PL198798B1 (pl
Inventor
WalterElger Walter Elger
KristofChwalisz Kristof Chwalisz
GerdSchubert Gerd Schubert
Original Assignee
Jenapharm Gmbh & Co.Kgjenapharm Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co.Kgjenapharm Gmbh & Co.Kg filed Critical Jenapharm Gmbh & Co.Kgjenapharm Gmbh & Co.Kg
Publication of PL353931A1 publication Critical patent/PL353931A1/pl
Publication of PL198798B1 publication Critical patent/PL198798B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL353931A 1999-08-31 2000-08-31 Zastosowanie mezoprogestyny J867, J912 i J956 PL198798B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38614099A 1999-08-31 1999-08-31
PCT/US2000/023771 WO2001034126A2 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)

Publications (2)

Publication Number Publication Date
PL353931A1 true PL353931A1 (pl) 2003-12-15
PL198798B1 PL198798B1 (pl) 2008-07-31

Family

ID=23524333

Family Applications (1)

Application Number Title Priority Date Filing Date
PL353931A PL198798B1 (pl) 1999-08-31 2000-08-31 Zastosowanie mezoprogestyny J867, J912 i J956

Country Status (33)

Country Link
EP (1) EP1605924B1 (pl)
JP (1) JP2003513908A (pl)
KR (1) KR100729311B1 (pl)
CN (1) CN1454088A (pl)
AR (1) AR025456A1 (pl)
AT (1) ATE413168T1 (pl)
AU (1) AU781836B2 (pl)
BG (1) BG65846B1 (pl)
BR (1) BR0013710A (pl)
CA (1) CA2383659C (pl)
CO (1) CO5200773A1 (pl)
CZ (1) CZ301412B6 (pl)
DE (1) DE60040764D1 (pl)
EA (1) EA007840B1 (pl)
EE (1) EE200200102A (pl)
ES (1) ES2316402T3 (pl)
HR (1) HRP20020266A2 (pl)
HU (1) HUP0202460A3 (pl)
IL (2) IL148417A0 (pl)
LT (1) LT5011B (pl)
LV (1) LV12942B (pl)
MX (1) MXPA02002190A (pl)
NO (1) NO20021000L (pl)
NZ (1) NZ517469A (pl)
PE (1) PE20010581A1 (pl)
PL (1) PL198798B1 (pl)
RO (1) RO122180B1 (pl)
RS (1) RS50396B (pl)
SI (1) SI20851B (pl)
SK (1) SK287121B6 (pl)
UA (1) UA75339C2 (pl)
WO (1) WO2001034126A2 (pl)
ZA (1) ZA200201621B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
ES2273061T3 (es) * 2002-08-02 2007-05-01 Schering Aktiengesellschaft Agentes moduladores de receptores de progesterona con actividad antigonadotropa elevada para el control de fertilidad femenina y para la terapia por reemplazo hormonal.
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2611370C1 (ru) * 2016-01-12 2017-02-21 Общество с ограниченной ответственностью Медицинская Корпорация "РАНА" Применение препарата Лаеннек для уменьшения или устранения проявления менопаузальных симптомов (варианты)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4225623C2 (de) * 1992-08-03 1994-06-30 Karl Hehl Verfahren zur Herstellung einer pulverförmigen Spritzgußmasse für die Herstellung von Porzellan und deren Verwendung
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
CA2203541A1 (en) * 1994-10-24 1996-05-02 Kristof Chwalisz Competitive progesterone antagonists for demand-oriented female birth control
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
NZ332894A (en) * 1996-06-25 1999-05-28 Akzo Nobel Nv A regimen containing progestogen and/or estrogen with two or more anti-progestogen dosage units
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
WO2000042031A2 (en) * 1999-01-14 2000-07-20 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

Also Published As

Publication number Publication date
SK287121B6 (sk) 2009-12-07
BR0013710A (pt) 2002-05-07
KR20020027618A (ko) 2002-04-13
ZA200201621B (en) 2004-08-25
EP1605924A2 (en) 2005-12-21
BG106443A (bg) 2002-09-30
AU781836B2 (en) 2005-06-16
CN1454088A (zh) 2003-11-05
AU3633201A (en) 2001-06-06
CZ2002706A3 (cs) 2002-10-16
UA75339C2 (en) 2006-04-17
IL148417A (en) 2010-11-30
NO20021000L (no) 2002-03-14
YU14102A (sh) 2006-01-16
MXPA02002190A (es) 2002-09-30
RO122180B1 (ro) 2009-02-27
RS50396B (sr) 2009-12-31
EP1605924B1 (en) 2008-11-05
LV12942B (en) 2003-06-20
BG65846B1 (bg) 2010-03-31
IL148417A0 (en) 2002-09-12
CA2383659A1 (en) 2001-05-17
PL198798B1 (pl) 2008-07-31
JP2003513908A (ja) 2003-04-15
WO2001034126A3 (en) 2001-11-22
CO5200773A1 (es) 2002-09-27
EA007840B1 (ru) 2007-02-27
EE200200102A (et) 2003-04-15
CZ301412B6 (cs) 2010-02-24
NZ517469A (en) 2004-01-30
CA2383659C (en) 2009-02-10
NO20021000D0 (no) 2002-02-28
ATE413168T1 (de) 2008-11-15
DE60040764D1 (de) 2008-12-18
PE20010581A1 (es) 2001-06-04
SI20851B (sl) 2009-06-30
SI20851A (sl) 2002-10-31
WO2001034126A2 (en) 2001-05-17
HUP0202460A3 (en) 2004-04-28
ES2316402T3 (es) 2009-04-16
HUP0202460A2 (hu) 2002-12-28
KR100729311B1 (ko) 2007-06-19
SK2972002A3 (en) 2002-07-02
LT2002037A (en) 2002-11-25
WO2001034126A9 (en) 2002-09-12
AR025456A1 (es) 2002-11-27
HRP20020266A2 (en) 2004-08-31
EA200200285A1 (ru) 2002-08-29
LT5011B (lt) 2003-04-25

Similar Documents

Publication Publication Date Title
HUP0200416A3 (en) Pharmaceutical composition useful for low dose estrogen interrupted hormone replacement therapy
PL374708A1 (pl) Tricykliczne modulatory jądrowego receptora steroidowego hormonu
EG25606A (en) Glucocorticoid receptor modulators
HUP0103345A3 (en) Use of estrogen receptor modulators in combination with sexual steroid precursors for the preparation of pharmaceutical compositions
HUP0204337A3 (en) Bicyclic androgen and progesterone receptor modulator compounds and pharmaceutical compositions containing them
AU2472997A (en) A novel composition for transdermal administration of an estrogen, a progestin or a mixture thereof
PL345588A1 (en) Use of biogenic estrogen sulfamates for hormone replacement therapy
AU5025300A (en) Compositions for controlled release of the hormone gnrh and its analogs
IL146057A0 (en) Process for the preparation of non-steroidal glucocorticoid receptor modulators
EP1143948A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
EP1157038A4 (en) CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
IL144031A0 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
IL148417A0 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
AU9621598A (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
HUP0202515A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
AU2002235348A1 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
SG114650A1 (en) Cyclocarbamate derivatives as progesterone receptor modulators
HUP9901474A3 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
GB9927215D0 (en) Hormone receptor expression
AU8146398A (en) Coup-tfii: an orphan nuclear receptor required for angiogenesis
AU2003206424A1 (en) Sequential estrogen/progesterone antagonist combination for hormone replacement therapy
AU5550099A (en) A novel retinal nuclear hormone receptor
HK1043789A1 (zh) 作为黄体酮受体调节剂的环硫代胺基甲酸盐衍生物
HK1043989A1 (zh) 作为黄体酮受体调节剂的环胺基甲酸盐衍生物
TWI293247B (en) Pharmaceutical compositions of a selective estrogen receptor modulator in combination with sex steroid precursors (2)

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20100831